The incidence of acute kidney injury in hospitalized patients receiving aminoglycoside antibiotics: a retrospective study
X. Huang, Y.-X. Liu, J.-H. Lao, J. Cao, X. Li, W.-B. Yao School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing, China. wbyao@cpu.edu.cn
OBJECTIVE: Our aim is to investigate the incidence and risk factors of acute kidney injury (AKI) in hospitalized patients who received aminoglycoside antibiotics.
MATERIALS AND METHODS: A retrospective analysis was performed on the electronic medical record information of inpatients who received aminoglycoside (AG) antibiotics in our center from January 2018 to December 2020. The diagnosis of AKI was based on serum creatinine changes. Several statistical methods, including chi square test and two sample Wilcoxon rank sum test, were used to evaluate the epidemiological characteristics of aminoglycosides associated AKI. The multivariate logistic regression analysis was used to screen the risk factors.
RESULTS: Finally, 8,040 patients who received AGs were included in the study. Among them, 494 patients (6.14%) were judged as incidence with AKI, while only 29 patients were diagnosed with AKI in the medical record. The multiple logistic regression analysis suggested that admission to ICU, complicated with diabetes mellitus, heart failure, anemia, shock, combined use of diuretics, β-lactam antibiotics, proton pump inhibitors were independent risk factors for AKI related to aminoglycosides.
CONCLUSIONS: It is urgent to improve the understanding and attention of AKI for medical workers, and the assessment of risk factors before the use of aminoglycosides should be contributed to the early prevention, diagnosis, and treatment of AKI.
Free PDF DownloadThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
To cite this article
X. Huang, Y.-X. Liu, J.-H. Lao, J. Cao, X. Li, W.-B. Yao
The incidence of acute kidney injury in hospitalized patients receiving aminoglycoside antibiotics: a retrospective study
Eur Rev Med Pharmacol Sci
Year: 2022
Vol. 26 - N. 10
Pages: 3718-3725
DOI: 10.26355/eurrev_202205_28868